Elena Nikulina

AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor

AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor
Verastem, Inc. reveals KRAS inhibitor data

Verastem, Inc. has announced the presentation of preclinical results for its investigational oral KRAS G12D (ON/OFF) inhibitor, VS-7375, at this year's AACR Meeting.

The company claims VS-7375 shows significant differentiation from other RAS inhibitors, positioning it as a potential best-in-class therapy in its category. Details regarding the efficacy and comparative advantages of VS-7375 were shared to underscore Verastem, Inc.'s ongoing commitment to innovation in targeted oncology treatments.

The company’s emphasis on advancing targeted oncology treatments builds on strategic priorities detailed in its recent Q4 and year end 2025 results and business update, where Verastem, Inc. outlined continued progress across its RAS/MAPK pipeline. This latest preclinical data on VS-7375 further illustrates the firm’s pursuit of therapeutic innovation within a highly competitive landscape.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.